[go: up one dir, main page]

WO2022258814A1 - Méthodes de traitement de la dermatite atopique et d'affections correspondantes - Google Patents

Méthodes de traitement de la dermatite atopique et d'affections correspondantes Download PDF

Info

Publication number
WO2022258814A1
WO2022258814A1 PCT/EP2022/065851 EP2022065851W WO2022258814A1 WO 2022258814 A1 WO2022258814 A1 WO 2022258814A1 EP 2022065851 W EP2022065851 W EP 2022065851W WO 2022258814 A1 WO2022258814 A1 WO 2022258814A1
Authority
WO
WIPO (PCT)
Prior art keywords
binding protein
subject
antibody
weeks
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2022/065851
Other languages
English (en)
Inventor
Thomas Mark
Lise SOLDBRO
Christian Bjerregaard ØLAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Priority to JP2023575802A priority Critical patent/JP2024522620A/ja
Priority to CA3221119A priority patent/CA3221119A1/fr
Priority to IL309053A priority patent/IL309053A/en
Priority to AU2022289697A priority patent/AU2022289697A1/en
Priority to US18/566,712 priority patent/US20250059269A1/en
Priority to EP22733594.0A priority patent/EP4351641A1/fr
Publication of WO2022258814A1 publication Critical patent/WO2022258814A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the present invention relates to methods for treating atopic dermatitis in a subject using an interleukin- 13 (IL-13) binding protein, such as an anti-IL-13 antibody or an IL- 13 -binding fragment thereof.
  • an interleukin- 13 (IL-13) binding protein such as an anti-IL-13 antibody or an IL- 13 -binding fragment thereof.
  • Atopic dermatitis is a heterogeneous inflammatory skin disease arising from genetic and environmental factors that disrupt skin barrier function and immune response (Leung, D.Y. and Guttman-Yassky, E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014; 134: 769-779).
  • Current management generally involves treatment combinations to suppress inflammation, restore skin barrier function, and prevent superinfection (Wollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B. et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. JEur Acad Dermatol Venereol. 2016; 30: 729-747).
  • Topical corticosteroids are overwhelmingly the most frequently prescribed class of drugs for AD patients, although long-term application of a TCS is not recommended.
  • Topical calcineurin inhibitors are generally effective and safe as short-term treatments. Skin malignancies and increased risk of lymphomas have prompted regulatory authorities to require a warning regarding the long-term safety of topical tacrolimus and pimecrolimus in their prescribing information, for example.
  • First generation antihistamines are widely prescribed for acute symptomatic treatment of pruritus (itching), although their effectiveness is limited and largely attributed to their sedating effect.
  • Oral immunosuppressants and glucocorticoids are effective, but are sometimes associated with severe toxicity and side effects, thus limiting their use to short term and/or intermittent therapy.
  • Cyclosporine A CSA
  • CSA Cyclosporine A
  • humoral and cellular immune responses which increases susceptibility to infections and decreases cancer immunosurveillance.
  • Other commonly recognized toxicities include hypertension and impaired renal and hepatic function.
  • CSA interacts with other commonly used drugs, potentially affecting their metabolism and effect.
  • Systemic immunosuppressants are typically reserved for treatment of moderate-to-severe AD because of their associated with adverse events and unsuitability for long-term use (Wollenberg, A., Oranje, A., Deleuran, M., Simon, D., Szalai, Z., Kunz, B. et al.
  • AD A key feature of AD is upregulation of IL-13 and interleukin-4 (IL-4) in lesional and nonlesional skin, suggesting both cytokines can contribute to AD pathogenesis (see Nomura, I., Goleva, E., Howell, M.D., Hamid, Q.A., Ong, P.Y., Hall, C.F. et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003; 171: 3262-3269; Tazawa, T., Sugiura, H., Sugiura, Y., and Uehara, M.
  • AD severity is associated with increased IL-13 and associated chemokine mRNA and serum levels, whereas reductions in IL-13 concentrations have correlated with treatment response and improved clinical outcomes.
  • dupilumab a human mAb that inhibits both IL-4 and IL-13 signaling, has demonstrated improvements in AD symptoms, the relative contribution of each of these cytokines to AD pathogenesis is unclear.
  • dupilumab Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology 2020;158: 111- 122.ell0), suggesting that there are AD-specific predisposing factors. Since the introduction of dupilumab as a treatment for AD, conjunctivitis has been identified as an important adverse event, which has resulted in an increased collaboration with ophthalmologists (Agnihotri G et al. A Clinician’s Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis. Drugs in R&D 2019;19:311-318; Wollenberg et al. 2018; Wollenberg A et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract 2018).
  • IL-13 is a 114 amino acid cytokine with an unmodified molecular mass of approximately 12 kDa. IL-13 is most closely related to IL-4 with which it shares 30% sequence homology at the amino acid level.
  • the human IL-13 gene is located on chromosome 5q31 adjacent to the IL-4 gene. Although initially identified as a Th2 CD4 + lymphocyte derived cytokine, IL-13 is also produced by Thl CD4+ T-cells, CD8+ T lymphocytes NK cells, and non-T- cell populations such as mast cells, basophils, eosinophils, macrophages, monocytes and airway smooth muscle cells.
  • IL-13 has been linked with a number of diseases, in particular, diseases which are caused by an inflammatory response.
  • diseases which are caused by an inflammatory response.
  • administration of recombinant IL-13 to the airways of naive non-sensitised rodents was shown to cause many aspects of the asthma phenotype including airway inflammation, mucus production and airways hyper-responsiveness.
  • a similar phenotype was observed in a transgenic mouse in which IL-13 was specifically overexpressed in the lung. In this model, more chronic exposure to IL-13 also resulted in fibrosis.
  • IL-13 gene A number of genetic polymorphisms in the IL-13 gene have also been linked to allergic diseases.
  • a variant of the IL-13 gene in which the arginine residue at amino acid 130 is substituted with glutamine (Q130R) has been associated with bronchial asthma, atopic dermatitis and raised serum IgE levels.
  • Q130R arginine residue at amino acid 130 is substituted with glutamine
  • This particular IL-13 variant is also referred to as the Q110R variant (arginine residue at amino acid 110 is substituted with glutamine) by some groups who exclude the 20 amino acid signal sequence from the amino acid count.
  • Tralokinumab (also known as CAT-354 and BAK502G9) is a fully human therapeutic antibody that binds to and neutralizes IL-13, including the Q130R variant (see Popovic et al. J Mol. Biol. (2017) 429(2): 208-219; May, R.D., Monk, P.D., Cohen, E.S., Manuel, D., Dempsey, F., Davis, N.H. et al. Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol. 2012; 166: 177-193).
  • Tralokinumab has previously been tested in phase 2b study of 204 adults for the treatment of AD - where patients received 45 mg, 150 mg, or 300 mg of subcutaneous tralokinumab, or placebo, every 2 weeks for 12 weeks with concomitant topical glucocorticoids - and was found to improve change from baseline in Eczema Area Severity Index (EASI) score, together with improvements in Scoring atopic dermatitis (SCORAD), Dermatology Life Quality Index (DLQI), and pruritus numeric rating scale scores, as compared to placebo (Wollenberg . Allergy Clin. Immunol. (2019) 143(1): 135-141).
  • EASI Eczema Area Severity Index
  • SCORAD Scoring atopic dermatitis
  • DLQI Dermatology Life Quality Index
  • pruritus numeric rating scale scores as compared to placebo (Wollenberg . Allergy Clin. Immunol. (2019) 143(1): 135-14
  • the inventors have found that patients in which AD is inadequately controlled by therapeutic agents targeting both IL-13 and IL-4 signaling (e.g. an antibody like dupilumab) can be effectively treated with IL-13 binding proteins (e.g. an anti-IL13 antibody like tralokinumab).
  • therapeutic agents targeting both IL-13 and IL-4 signaling e.g. an antibody like dupilumab
  • IL-13 binding proteins e.g. an anti-IL13 antibody like tralokinumab
  • the invention provides an interleukin- 13 (IL-13) binding protein for use in a method of treating atopic dermatitis (AD) in a subject, wherein the AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signalling and wherein the method comprises administering the IL-13 binding protein to the subject.
  • AD atopic dermatitis
  • the method comprises selecting a subject whose AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signalling.
  • the invention provides a method of treating atopic dermatitis (AD) in a subject in need thereof, wherein the AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signalling, and wherein the method comprises the step of administering the IL-13 binding protein to the subject.
  • AD atopic dermatitis
  • the method comprises selecting a subject whose AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signalling.
  • the invention provides use of an IL-13 binding protein in the manufacture of a medicament for treating AD in a subject, wherein the AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signaling.
  • the AD may be moderate-to-severe AD or severe AD.
  • the invention provides an IL-13 binding protein for use in a method of treating atopic dermatitis in a subject who has experienced conjunctivitis when treated with an agent that inhibits IL-13 and IL-4 signalling, wherein the method comprises administering the IL-13 binding protein to the subject.
  • the invention provides a method for treating atopic dermatitis in a subject who has experienced conjunctivitis when treated with an agent that inhibits IL-13 and IL-4 signaling, wherein the method comprises administering the IL-13 binding protein to the subject.
  • the invention provides the use of an IL-13 binding protein in the manufacture of a medicament for treating atopic dermatitis in a subject who has experienced conjunctivitis when treated with an agent that inhibits IL-13 and IL-4 signaling, wherein the method comprises administering the IL-13 binding protein to the subject.
  • the method comprises selecting a subject who has experienced conjunctivitis when treated with an agent that inhibits IL-13 and IL-4 signaling.
  • the AD may be inadequately controlled by cyclosporine A or the subject may have contraindications to cyclosporine A.
  • the method may comprise steps of: (a) administering a first dose of the IL-13 binding protein to the subject; and (b) administering one or more secondary dose(s) of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject from 12 days to 35 days after the immediately preceding dose. In preferred embodiments, each secondary dose is administered to the subject about 12-16 days after the immediately preceding dose, or from
  • each secondary dose is administered to the subject about 2 weeks after the immediately preceding dose, or about 4 weeks after the immediately preceding dose.
  • the methods described herein are carried out for at least 2 weeks, at least 3 weeks, at least 12 weeks, at least 3 months, at least 16 weeks, at least 24 weeks, at least 26 weeks, at least 6 months, at least 32 weeks, at least 36 weeks, at least a year, or at least 52 weeks or more. In preferred embodiments, the methods are carried out for at least
  • the method may comprise the steps of: (a) administering a first dose of about 10 to about 600 mg of the IL 13 binding protein to the subject; and (b) administering one or more secondary dose(s) of about 10 to about 600 mg of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject from 12 days to 35 days after the immediately preceding dose.
  • the method may comprise the steps of: (a) administering a first dose of about 600 mg of the IL 13 binding protein to the subject; and (b) administering one or more secondary dose(s) of about 300 mg of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject from 12 days to 35 days after the immediately preceding dose.
  • each secondary dose is administered to the subject about 12-16 days after the immediately preceding dose, or from 25 days to 31 days after the immediately preceding dose. In a further preferred embodiment, each secondary dose is administered to the subject about 2 weeks after the immediately preceding dose, or about 4 weeks after the immediately preceding dose.
  • the IL-13 binding protein is an anti-IL-13 antibody, or an IL- 13- binding fragment thereof.
  • the IL-13 binding protein for use according to any of the methods described herein is an anti-IL-13 antibody, or IL-13 -binding fragment thereof, wherein the anti-IL-13 antibody, or IL-13 -binding fragment thereof comprises: a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence of SEQ ID NO: 1 ; a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence of SEQ ID NO:2; a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence of SEQ ID NO:3; a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence of SEQ ID NO:4; a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence of SEQ ID NO:5; and a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence of SEQ ID NO: 6.
  • HCDR1 heavy chain complementarity determining region 1
  • HCDR2 compris
  • the anti-IL-13 antibody, or IL-13 -binding fragment thereof comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein:
  • the heavy chain variable region comprises: a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence of SEQ ID NO: 1 ; a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence of SEQ ID NO:2; and a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence of SEQ ID NO:3; and
  • HCDR1 heavy chain complementarity determining region 1
  • HCDR2 heavy chain complementarity determining region 2
  • HCDR3 heavy chain complementarity determining region 3
  • the light chain variable region comprises: a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence of SEQ ID NO:4; a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence of SEQ ID NO:5; and a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence of SEQ ID NO: 6.
  • LCDR1 light chain complementarity determining region 1
  • LCDR2 light chain complementarity determining region 2
  • LCDR3 comprising an amino acid sequence of SEQ ID NO: 6.
  • the anti-IL-13 antibody, or IL- 13 -binding fragment thereof comprises a heavy chain variable region sequence of SEQ ID NO: 8 and a light chain variable region sequence of SEQ ID NO: 10.
  • the anti-IL-13 antibody, or IL- 13 -binding fragment thereof comprises a heavy chain of SEQ ID NO: 11 and a light chain sequence of SEQ ID NO: 12.
  • the anti-IL-13 antibody is tralokinumab.
  • the IL-13 binding protein may be administered as a monotherapy or as a combination therapy with a second therapeutic agent.
  • the IL-13 binding protein is administered in combination with a topical corticosteroid.
  • the subject treated by the IL-13 binding protein in the methods described herein have AD, wherein the AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signalling.
  • the agent that inhibits IL-13 and IL-4 signalling may be an antibody or antigen binding fragment thereof.
  • the agent that inhibits IL-13 and IL-4 signalling is an antibody or antigen binding fragment thereof that binds to IL-4Ra.
  • the agent that inhibits IL-13 and IL-4 signalling is dupilumab.
  • EASI-50 Eczema Area and Severity Index
  • the methods described herein achieve >75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline.
  • EASI-50 or EASI-75 is achieved at week 16. In some embodiments, EASI-50 or EASI-75 is achieved at week 26.
  • the method comprises (a) administering a first dose of about 600 mg of the IL-13 binding protein to the subject; and (b) administering one or more secondary dose(s) of about 300 mg of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject 2 weeks after the immediately preceding dose, wherein the IL-13 binding protein is an antibody comprising a heavy chain variable region sequence of SEQ ID NO: 8 and a light chain variable region sequence of SEQ ID NO: 10 (e.g. tralokinumab), wherein the method is carried out for at least 26 weeks and wherein the method achieves >75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline at 26 weeks.
  • EASI-75 Eczema Area and Severity Index
  • the IL-13 binding protein is administered in combination with a topical corticosteroid and/or (ii) the AD is inadequately controlled by cyclosporine A or the subject has contraindications to cyclosporine A.
  • Figure 1 shows the trial design for the ECZTRA7 trial.
  • the invention relates to methods for treating atopic dermatitis (AD) in a subject using an interleukin- 13 (IL-13) binding protein (e.g. an anti-IL-13 antibody or an IL-13-binding fragment thereof, such as tralokinumab), wherein the AD is inadequately controlled by an agent which inhibits IL-13 and IL-4 signaling (such as dupilumab).
  • IL-13 interleukin- 13
  • an agent which inhibits IL-13 and IL-4 signaling such as dupilumab
  • Atopic dermatitis means an inflammatory skin disease characterized by intense pruritus (e.g. severe itch) and by scaly and dry eczematous lesions.
  • atopic dermatitis includes AD caused by or associated with epidermal barrier dysfunction, allergy (e.g. allergy to certain foods, pollen, maid, dust mite, animals, etc.), radiation exposure, and/or asthma.
  • allergy e.g. allergy to certain foods, pollen, maid, dust mite, animals, etc.
  • radiation exposure e.g. asthma
  • asthma e.g. asthma, wh mite, animals, etc.
  • the present invention relates to moderate-to-severe or severe AD.
  • Moderate-to-severe AD is characterized by intensely pruritic, widespread skin lesions that are often complicated by persistent bacterial, viral or fungal infections. Moderate-to-severe AD also includes chronic AD. In many cases, the chronic lesions include thickened plaques of skin, lichenification and fibrous papules. In general, patients affected by moderate-to-severe AD also have more than 20% of the body's skin affected, or 10% of skin area in addition to involvement of the eyes, hands and body folds. Moderate- to-severe AD is also considered to be present in patients who frequently require treatment with a topical corticosteroid. In the clinical studies reported herein a subject with “moderate to severe AD” was a subject having an IGA score of 3-4.
  • Severe AD refers to chronic relapsing AD that is refractory to treatment with medium-potency and high-potency TCS and/or immunosuppressant therapy. Severe AD is also characterized by chronic intensely pruritic lesions affecting more than 20% of the body surface area. Severe AD can be considered to be present in subjects with chronic AD according to the Eichenfield criteria (Eichenfield et al 2014, J. Am. Acad. Dermatol. 70: 338-351), for which treatment with a potent topical corticosteroid (TCS) is indicated, and/or where the subject is resistant to treatment with a systemic corticosteroid and/or nonsteroidal immunosuppressant.
  • TCS potent topical corticosteroid
  • the method treats severe AD in a subject, where the subject has an IGA score of 4 at baseline.
  • a subject with “severe AD” may have AD on at least 10% of their body surface area at screening and baseline, an EASI score of >20 at screening and baseline, and an IGA score of >3 at screening and baseline.
  • the term "subject” includes human and non-human animals, particularly mammals. Typically, the subject is a human, as shown in the examples below.
  • Subjects treated by the methods of this invention are those with AD (especially moderate- to-severe AD or severe AD) who have previously been treated with a therapeutic agent that inhibits both IL-13 and IL-4 signalling, such as an anti-IL4Ra antibody (e.g. dupilumab), but their AD is inadequately controlled with this agent.
  • a therapeutic agent that inhibits both IL-13 and IL-4 signalling such as an anti-IL4Ra antibody (e.g. dupilumab)
  • an anti-IL4Ra antibody e.g. dupilumab
  • “inadequately controlled” by an agent that inhibits IL-13 and IL-4 signalling means that the AD is non-responsive, resistant or refractory to an agent that inhibits IL-13 and IL-4 signalling”, such as an anti-IL4Ra antibody (e.g. dupilumab).
  • an agent that inhibits IL-13 and IL- 4 signalling such as an anti-IL4Ra antibody (e.g. dupilumab) did not have a therapeutic effect.
  • a subject with moderate-to-severe AD or severe AD (such as those with chronic relapsing AD) that has been treated with an agent that inhibits IL-13 and IL-4 signalling (e.g. dupilumab) did not show a decrease in one or more AD-associated parameter score(s), as described in more detail below.
  • an agent that inhibits IL-13 and IL-4 signalling e.g. dupilumab
  • the time for the assessment of a therapeutic effect will vary depending on the typical timeframe for onset of action of the agent that inhibits IL-13 and IL-4.
  • the term “inadequately controlled”, “non-responsive”, “resistant” or “refractory” to an agent that inhibits IL-13 and IL-4 signalling refers to a subject with AD that has been treated with an agent that inhibits IL-13 and IL-4 signalling (e.g. dupilumab), but wherein the agent did not have a therapeutic effect e.g. wherein the method did not achieve >50% improvement of Eczema Area and Severity Index (EASI-50) compared to baseline or >75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline, for example at week 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
  • the agent that inhibits IL-13 and IL-14 signalling is an antibody. In preferred embodiments, the agent that inhibits IL-13 and IL-14 signalling is dupilumab.
  • dupilumab treatment has been deemed not medically advisable by a physician for the subject.
  • a subject may be identified by the following criteria: (1) not currently a candidate for dupilumab treatment due to: medical contraindication(s); hypersensitivity to dupilumab or excipient(s); use of concomitant medications prohibited with dupilumab; (2) previous intolerance, side effects and/or unacceptable toxicity on previous exposure to dupilumab; and/or (3) requirement for dupilumab at doses or duration beyond that specified in the prescribing information.
  • dupilumab Common side effects associated with dupilumab include conjunctivitis, eosinophilia; eye inflammation; eye pruritus; headache; oral herpes.
  • use of dupilumab has been discontinued in a subject due to adverse side effects, for example due to conjunctivitis.
  • the invention provides an IL-13 binding protein for use in a method of treating atopic dermatitis in a subject who has experienced conjunctivitis when treated with an anti-IL4Ra antibody or an antibody that inhibits IL-4 and IL-13 signalling, e.g. dupilumab, wherein the method comprises administering the IL-13 binding protein to the subject.
  • the invention provides an IL-13 binding protein for use in a method of treating atopic dermatitis in a subject, wherein the method comprises the steps of: (a) selecting a subject who has experienced conjunctivitis when treated with an anti-IL4Ra antibody or an antibody that inhibits IL-4 and IL-13 signalling, e.g. dupilumab; and (b) administering the IL-13 binding protein to the subject.
  • the invention provides a method for treating atopic dermatitis in a subject who has experienced conjunctivitis when treated with an anti-IL4Ra antibody or an antibody that inhibits IL-4 and IL-13 signalling, e.g. dupilumab, wherein the method comprises administering the IL-13 binding protein to the subject.
  • the invention provides a method for treating atopic dermatitis in a subject, wherein the method comprises the steps of: (a) selecting a subject who has experienced conjunctivitis when treated with an anti-IL4Ra antibody or an antibody that inhibits IL-4 and IL-13 signalling, e.g. dupilumab; and (b) administering the IL-13 binding protein to the subject.
  • the invention provides the use of an IL-13 binding protein in the manufacture of a medicament for treating atopic dermatitis in a subject who has experienced conjunctivitis when treated with an anti-IL4Ra antibody or an antibody that inhibits IL-4 and IL-13 signalling, e.g. dupilumab, wherein the method comprises administering the IL-13 binding protein to the subject.
  • the invention provides the use of an IL-13 binding protein in the manufacture of a medicament for treating atopic dermatitis in a subject, wherein the method comprises the steps of: (a) selecting a subject who has experienced conjunctivitis when treated with an anti-IL4Ra antibody or an antibody that inhibits IL-4 and IL-13 signalling, e.g. dupilumab; and (b) administering the IL-13 binding protein to the subject.
  • a subject with AD may also be resistant, non-responsive or inadequately responsive to treatment with a non-steroid systemic immunosuppressant.
  • non-steroid systemic immunosuppressant includes cyclosporine A (CSA), methotrexate, mycophenolate mofetil, azathioprine, and interferon-gamma.
  • CSA cyclosporine A
  • methotrexate e.g. an anti-TNFa antibody such as infliximab
  • CDlla inhibitors e.g. an anti-CDlla antibody such as efalizumab
  • IgE inhibitors e.g.
  • the methods described herein may treat AD in subjects that are resistant, nonresponsive (refractory) or inadequately responsive to treatment with a systemic immunosuppressant.
  • resistant, non-responsive or inadequately responsive to a systemic immunosuppressant refers to a subject with AD that has been treated with a systemic immunosuppressant and the immunosuppressant did not have a therapeutic effect, e.g.
  • a subject with moderate-to-severe AD or severe AD (such as those with chronic relapsing AD) that has been treated with a non-steroid systemic immunosuppressant for between 1-3 months and did not show a decrease in one or more AD-associated parameter score(s).
  • the time for the assessment of a therapeutic effect will vary depending on the typical timeframe for onset of action of the non-steroid systemic immunosuppressant. Such timeframes are well known. For example, for cyclosporine the onset of action is typically 2-6 weeks, but for other non-steroid systemic immunosuppressants it is typically around 8-12 weeks.
  • immunosuppressant treatment has been deemed not medically advisable by a physician for the subject.
  • a subject may be identified by the following criteria: (1) not currently a candidate for immunosuppressant treatment due to: medical contraindication(s); or hypersensitivity to the immunosuppressant or excipient(s); use of concomitant medications prohibited with immunosuppressant; or increased susceptibility to immunosuppressant induced renal damage or increased risk of serious infections; (2) previous intolerance and/or unacceptable toxicity on previous exposure to an immunosuppressant; and/or (3) requirement for immunosuppressant at doses or duration beyond that specified in the prescribing information.
  • medical contraindication(s) or hypersensitivity to the immunosuppressant or excipient(s)
  • concomitant medications prohibited with immunosuppressant or increased susceptibility to immunosuppressant induced renal damage or increased risk of serious infections
  • (2) previous intolerance and/or unacceptable toxicity on previous exposure to an immunosuppressant and/or (3) requirement for immunosup
  • the subject may be one in which the atopic dermatitis is not adequately controlled by cyclosporine A (CSA), e.g. oral cyclosporine A, or the subject has contraindications to cyclosporine A (CSA), e.g. oral cyclosporine A.
  • CSA cyclosporine A
  • CSA cyclosporine A
  • An inadequate response to CSA is defined as flare of AD on CSA tapering after a maximum of 6 weeks of high dose (5 mg/kg/day) to maintenance dose (2 to 3 mg/kg/day) or a flare after a minimum of 3 months on maintenance dose. Flare is defined as increase in signs or symptoms leading to escalation of therapy, which could be an increase in dose, a switch to a higher potency class of TCS, or the start of another systemic non-steroidal immunosuppressive drug.
  • Contraindications to CSA include: i. medical contraindications (e.g. uncontrolled hypertension on medication) or hypersensitivity to CSA active substance or excipients; ii. use of prohibited concomitant medications (e.g. statins, digoxin, macrolide, antibiotics, barbiturates, anti-seizure, non-steroidal anti-inflammatory drugs, diuretics, angiotensin-converting-enzyme inhibitors, St John's Wort); iii. increased susceptibility to CSA-induced renal damage (elevated creatinine) and liver damage (elevated function tests), or increased risk of serious infections; iv. intolerance or unacceptable toxicity (e.g. elevated creatinine, elevated liver function tests, uncontrolled hypertension, paraesthesia, headache, nausea, hypertrichosis), or v. requirement for CSA at doses >5 mg/kg/day, or duration beyond those specified in the prescribing information (>1 year).
  • prohibited concomitant medications e.g. stat
  • the invention relates to IL-13 binding proteins for treating AD in subjects, wherein the AD is not adequately controlled by an agent that inhibits IL-13 and IL-4 signalling.
  • Agents that inhibit IL-13 and IL-4 signalling include for example, antibodies or antigen binding fragments thereof, as well as small molecule inhibitors and IL-4 muteins.
  • the agent that inhibits IL-4 and IL-13 signalling is an antibody or antigen binding fragment thereof.
  • the antigen binding fragment can be selected from a Fab, Fab', F(ab')2, Fd, Fv, single-chain Fv (scFv), or disulfide-linked Fvs (sdFv).
  • the agent that inhibits IL-13 and IL-4 signalling is an antibody or antigen binding fragment thereof that binds to IL-4Ra.
  • antibodies that bind to IL-4Ra include dupilumab.
  • the antibody that inhibits IL-13 and IL-4 signalling is dupilumab.
  • the methods described herein treat AD.
  • the terms “treat”, “treating”, “treatment”, or the like mean to alleviate (reduce, minimise, or eliminate) symptoms, or to reduce, minimise or eliminate the causation of symptoms either on a temporary or permanent basis.
  • AD-associated parameters are available to measure the severity of AD and the impact of a drug on AD. These include Investigators Global Assessment (IGA); Eczema Area and Severity Index (EASI); SCORing Atopic Dermatitis (SCORAD); and/or pruritus Numeric Rating Scale (NRS).
  • IGA Investigators Global Assessment
  • EASI Eczema Area and Severity Index
  • NRS pruritus Numeric Rating Scale
  • the methods described herein may improve in an AD- associated parameter in the subject. Alternately, the methods may maintain improvement in an AD-associated parameter in the subject.
  • the AD-associated parameter may be selected from: Investigators Global Assessment (IGA); Eczema Area and Severity Index (EASI); Scoring atopic dermatitis (SCORAD); and/or pruritus Numeric Rating Scale (NRS).
  • the IGA is an instrument used in clinical trials to rate the severity of the subject’s global AD and is based on a 5 -point scale ranging from 0 (clear) to 4 (severe) based on the condition of the disease at the time of evaluation.
  • the EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD (Hanifin et al. “The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Experimental dermatology” (2001) 10(1): 11-18).
  • SCORAD is one of the most commonly used disease severity scores in clinical trials with AD and in clinical practice (see “ European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis” Dermatology (1993) 186(1): 23- 31).
  • Worst Daily Pruritus NRS is established according to FDA and EMA recommendations (see, e.g. FDA “ The Food and Drug Administration. Guidance for Industry. Patient- Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. 2009” and EMA “Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQoL) measures in the evaluation of medicinal products. EMEA/CHMP/EWP/139391/2004. 2005).
  • HRQoL health-related quality of life
  • An improvement in this context can be a reduction in IGA score, a reduction in EASI score, a reduction in SCORAD score (where >50 severe, 25-50 is moderate, ⁇ 25 is mild), reduction in pruritus NRS score, where each score is compared to baseline.
  • the baseline is an initial measurement of an AD-associated parameter or patient-related outcome (or any other parameter) that is taken before initiation of treatment by the method described herein, i.e. a measurement taken before the "baseline dose" (defined elsewhere).
  • an Investigator’s Global Assessment 0 or 1 (IGA 0/1; clear or almost clear skin) and/or > 75% improvement of Eczema Area and Severity Index (EASI-75) are the regulatory primary efficacy endpoints in Phase 3 clinical trials in AD.
  • the methods described herein may preferably achieve or maintain an Investigator’s Global Assessment (IGA) score of 0 or 1 and/or > 75% improvement of Eczema Area and Severity Index (EASI-75) over baseline (e.g. as shown in Examples 1 and 2 herein).
  • the methods may achieve or maintain a > 50% improvement of Eczema Area and Severity Index (EASI-50) over baseline.
  • the methods described herein may improve at least one patient-related outcome (PRO) selected from the group consisting of: worst daily pruritus Numerical Rating Scale (NRS) (see pruritus NRS discussed above), eczema-related sleep interference, Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Patient Global Impression of Bother (PGI-B), Hospital Anxiety and Depression Scale (HADS), Short Form (36) Health Survey (SF-36) and EuroQoL 5 -Dimension Health Questionnaire 5 Level (EQ-5D-5L) .
  • NRS worst daily pruritus Numerical Rating Scale
  • POEM Patient Oriented Eczema Measure
  • DLQI Dermatology Life Quality Index
  • PKI-B Patient Global Impression of Bother
  • HADS Hospital Anxiety and Depression Scale
  • SF-36 Short Form
  • EuroQoL 5 -Dimension Health Questionnaire 5 Level EQ-5D-5L
  • eczema-related sleep interference NRS For eczema-related sleep interference NRS, a subject rates how much their eczema interfered with their sleep the previous night using an 11 point NRS from 0 (no interference) to 10 (complete interference).
  • the POEM is a validated questionnaire used to assess disease symptoms in AD patients in both clinical practice and clinical trials (see Charman et al. “The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients perspective ” Arch Dermatol. (2004) 140(12): 1513-1519).
  • DLQI is a patient-reported validated questionnaire with content specific to subjects with dermatology conditions (see Finlay et al.
  • DLQI Dermatology Life Quality Index
  • PKI-B Patient Global Impression of Bother
  • a 5 -point categorical response scale will be used (‘not at all’, ‘slightly’, ‘somewhat’, ‘a lot’, ‘very much’).
  • the Hospital Anxiety and Depression Scale (HADS) is a Likert-scale tool widely used to detect states of anxiety and depression in a general hospital setting (see Zigmond AS, Snaith RP. "The hospital anxiety and depression scale”.
  • the tool consists of 14 items that assess the subject’s anxiety (7 items) and depression (7 items) during the last week. Each item is scored from 0 to 3, with high scores indicating more severe anxiety or depression.
  • Short Form (36) Health Survey (SF-36) is a patient-reported survey designed to evaluate health status by generating scores for 8 health domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health) and 2 psychometrically derived summary scores (a physical component summary and a mental component summary) (see Ware JEJ, Sherboume CD. "The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection” Med Care.
  • EuroQoL 5-Dimension Health Questionnaire 5 Level is a standardised measure of health status developed by the EuroQoL group to provide a simple, generic measure of health for clinical and economic appraisal (see Greiner W et al. ”A single European currency for EQ-5D health states. Results from a six-country study” The European journal of health economics: HEP AC : health economics in prevention and care. 2003;4(3):222-31).
  • the EQ-5D-5L is a self-administered questionnaire used to assess health status ‘today’ and is divided into 2 sections:
  • the first section includes 5 dimensions (mobility, self-care, usual activity, pain/discomfort, and anxiety/depression); each dimension is assessed by the subject using a 5-point scale (‘no problems’, ‘slight problems’, ‘moderate problems’, ‘severe problems’, and ‘extreme problems’).
  • the second section consists of a vertical visual analogue scale anchored at 0 (‘the worst health you can imagine’) and 100 (‘the best health you can imagine’).
  • the methods may maintain improvement in at least one patient-related outcome (PRO) selected from the group consisting of: worst daily pruritus Numerical Rating Scale (NRS), eczema-related sleep interference, Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), Patient Global Impression of Bother (PGI-B), Hospital Anxiety and Depression Scale (HADS), Short Form (36) Health Survey (SF-36) and EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L).
  • PRO patient-related outcome
  • PRO patient-related outcome
  • the improvement or maintained improvement is relative to baseline.
  • An improvement in this context can be a reduction (e.g. a > 3 point reduction) in the PRO score (or, for example, a > 4 point reduction for DLQI), where the score is compared to baseline.
  • the method described herein may achieve: (a) > 50% improvement of Eczema Area and Severity Index (EASI-50); and/or (b) > 75% improvement of Eczema Area and Severity Index (EASI-75) (e.g. after 16 weeks or after 26 weeks, as illustrated in Examples 1 and 2).
  • TCS Long-term application of a TCS is not recommended because of the risk of skin atrophy, dyspigmentation, acneiform eruptions, and risks associated with systemic absorption (e.g. hypothalamic pituitary axis effects, Cushing's disease, etc.). Repeated application of any topical therapy over a long period of time or to large surface areas can also lead to reduced patient compliance.
  • the methods described herein may reduce the topical corticosteroid (TCS) dependence of the subject with AD (especially moderate-to-severe or severe AD).
  • TCS topical corticosteroid
  • Reduced dependence may be assessed by comparing the cumulative amount (in grams) of a formulation containing TCS applied by a subject after initiation of a method described herein over a particular time interval (e.g. 16 weeks or 26 weeks), as compared to a placebo-treated subject.
  • a subject may use at least 0.2 g less, at least 0.3 g less, at least 0.4 g less or at least 0.5 g less TCS per day, as compared to a placebo-treated subject.
  • a subject may use at least 0.5 g less TCS per day, as compared to a placebo-treated subject.
  • Reduced dependence may also be assessed by the number of TCS-free days (which may still include lower potency TCS and TCI) after initiation of the method, as compared to the same measurement performed at baseline.
  • a TCS can be classified as group I, group II, group III and group IV topical corticosteroid.
  • corticosteroids are classified as weak/lower potency (group I), moderately potent (group II) and potent (group III) and very potent (group IV), based on their activity as compared to hydrocortisone.
  • Group IV TCS very potent are up to 600 times as potent as hydrocortisone and include clobetasol propionate and halcinonide.
  • Group III TCS are 50 to 100 times as potent as hydrocortisone and include betamethasone valerate, betamethasone dipropionate, diflucortolone valerate, hydrocortisone- 17-butyrate, mometasone furoate, and methylprednisolone aceponate.
  • Group II TCS are 2 to 25 times as potent as hydrocortisone and include clobetasone butyrate, and triamcinolone acetonide.
  • Group I TCS (mild) includes hydrocortisone.
  • TCS-free day means a day in which the subject does not use a TCS of Group II, Group III or Group IV.
  • the subject the number of TCS-free days may increase by about 0.5 day, about 0.75 day, about 1 day, about 1.5 days, about 2 days, about 3 days or more averaged over a week, as compared to a placebo-treated subject.
  • the number of TCS-free days may increase by about 0.5 day, as compared to a placebo-treated subject.
  • the IL-13 binding protein can be administered as a monotherapy e.g. without TCS.
  • the IL-13 binding protein is administered in combination with a second therapeutic agent selected from the group consisting of a TCS, a topical calcineurin inhibitor, an anti-histamine, an emollient, or an anti-bacterial therapeutic.
  • the IL-13 binding protein is administered in combination with a TCS.
  • the IL-13 binding protein may be used in combination with a TCS so as to wean a subject off TCS use. Accordingly, in the methods described herein a medium-potency or high- potency TCS may be administered alongside the IL-13 binding protein.
  • the amount of TCS can then be reduced by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or around 100% after initiation of the method (e.g. over a 3-4 month period), as compared to the amount of TCS at baseline.
  • An IL-13 binding protein is a protein that specifically binds to and neutralizes human IL-13.
  • the term "specifically binds” means that a protein (such as an antibody or antigen-binding fragment thereof) forms a complex with an antigen that is relatively stable under physiological conditions.
  • Methods for determining whether a protein specifically binds to an antigen include, for example, equilibrium dialysis, surface plasmon resonance (e.g. using a BIAcore 200 Biosensor (BIAcore AB), and the like.
  • a protein such as an antibody or antigen-binding fragment thereof
  • Methods for determining whether a protein specifically binds to an antigen include, for example, equilibrium dialysis, surface plasmon resonance (e.g. using a BIAcore 200 Biosensor (BIAcore AB), and the like.
  • BIAcore 200 Biosensor BIAcore AB
  • an IL-13 binding protein e.g.
  • an anti-IL-13 antibody or IL-13 binding fragment thereof) that "specifically binds" IL-13 may bind IL-13 with a KD of less than about 1000 nM, less than about 500 nM, less than about 100 nM, less than about 50 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.25 nM, less than about 0.1 nM or less than about 0.05 nM, as measured by surface plasmon resonance at 25°C.
  • the exemplified antibody, tralokinumab binds human bound human IL-13 with a KD of 178 pM, as measured by surface plasmon resonance (see WO 2005/007699 for detailed methods). Accordingly, in a preferred embodiment, the anti-IL-13 antibody has a KD of less than about 200 pM, as measured by surface plasmon resonance at 37°C or 25°C.
  • an IL-13 binding protein specifically binds human IL-13, it may have cross-reactivity to other antigens, such as IL-13 from other (non-human) species.
  • Neutralisation activity can be measured in an IL-13 dependent TF-1 cell proliferation assay relative to a control antibody that is not directed to IL-13, as described in WO 2005/007699.
  • inhibition of IL-13 dependent proliferation is determined by measuring the reduction in incorporation of tritiated thymidine into the newly synthesized DNA of dividing cells.
  • Assay media comprises RPMI-1640 with GLUTAMAX I (Invitrogen) containing 5% FBS and 1% sodium pyruvate.
  • TF-1 cells Prior to each assay, TF-1 cells are pelleted by centrifugation at 300 x g for 5 minutes, the media removed by aspiration and the cells resuspended in assay media. This process is repeated twice with cells resuspended at a final concentration of 10 5 cells/mL in assay media.
  • Test solutions of antibody (in triplicate) are diluted to the desired concentration in assay media.
  • An antibody that is not directed at IL-13 is used as a negative control.
  • Recombinant bacterially derived human or murine IL-13 is added to a final concentration of 50 ng/mL when mixed with the appropriate test antibody in a total volume of 100 pL/well in a 96 well assay plate.
  • the concentration of IL-13 used in the assay is selected as the dose that at final assay concentration gives approximately 80% of the maximal proliferative response. All samples are incubated for 30 minutes at room temperature. 100 pL of resuspended cells are then added to each assay point to give a total assay volume of 200 pL/well. Assay plates are incubated for 72 hours at 37°C under 5% CO2. 25 pL of tritiated thymidine (10 pCi/mL) is then added to each assay point and assay plates are returned to the incubator for a further 4 hours. Cells are harvested on glass fibre filter plates (Perkin Elmer) using a cell harvester. Thymidine incorporation is determined using a Packard TopCount microplate liquid scintillation counter.
  • the IL-13 binding protein is an anti-IL-13 antibody or an IL-13 -binding fragment thereof.
  • each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
  • the heavy chain constant region comprises three domains, CHI, CH2 and CH3.
  • Each light chain comprises a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region.
  • the light chain constant region comprises one domain (CLI).
  • VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the FRs of the anti-IL-13 antibody may be identical to the human germline sequences, or may be naturally or artificially modified.
  • the heavy chain constant region of the antibodies may be from any types of constant region, such as IgG, IgM, IgD, IgA, and IgE.
  • the antibody is an IgG (e.g. isotype IgGl, IgG2, IgG3 or IgG4).
  • the antibody is an IgG4, as exemplified herein.
  • the antibody may be a mouse, human, primate, humanized or chimeric antibody.
  • the antibody may be polyclonal or monoclonal.
  • monoclonal and human (or humanized) antibodies are preferred.
  • the antibody is human or humanized, and monoclonal.
  • the antibody can be a multispecific (e.g. bispecific) antibody.
  • a multispecific antibody or antigen-binding fragment of an antibody will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen.
  • Any multispecific antibody format may be adapted for use in the context of an antibody or antigen binding fragment of an antibody as described herein using routine techniques available in the art. For example, the methods that use of bispecific antibodies, wherein one arm of an immunoglobulin is specific for IL-13, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated to a therapeutic moiety.
  • An IL-13 -binding fragment of an anti-IL-13 antibody may be any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide. Such fragments may be derived, e.g. from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains. Such DNA is known and/or is readily available from, e.g. commercial sources, DNA libraries (including, e.g. phage-antibody libraries), or can be synthesized.
  • the DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.
  • IL-13-binding fragments include: Fab, Fab', F(ab')2, Fd, Fv, single-chain Fv (scFv), disulphide-linked Fvs, dAb fragments, and other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g. monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains.
  • variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences.
  • the VH and VL domains may be situated relative to one another in any suitable arrangement.
  • the variable region may be dimeric and contain VH-VH, VH-VL or VL-VL dimers.
  • the antigen-binding fragment of an antibody may contain a monomeric VH or VL domain.
  • the anti-IL- 13 antibody, or an IL- 13 -binding fragment thereof may comprise: a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence of SEQ ID NO:l; a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence of SEQ ID NO:2; a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence of SEQ ID NO:3; a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence of SEQ ID NO:4; a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence of SEQ ID NO: 5; and a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence of SEQ ID NO:6.
  • HCDR1 heavy chain complementarity determining region 1
  • HCDR2 comprising an amino acid sequence of SEQ ID NO:2
  • HCDR3 comprising an amino acid sequence of SEQ ID NO:3
  • the anti-IL- 13 antibody, or an IL- 13 -binding fragment thereof may comprise a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein: (i) the heavy chain variable region comprises: a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence of SEQ ID NO:l; a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence of SEQ ID NO:2; and a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence of SEQ ID NO:3; and (ii) the light chain variable region comprises: a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence of SEQ ID NO:4; a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence of SEQ ID NO:5; and a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence of SEQ ID NO:6.
  • HCDR1 heavy chain complementar
  • the anti-IL-13 antibody, or an IL-13-binding fragment thereof may further comprise: (i) an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a heavy chain variable region sequence of SEQ ID NO: 8; and/or (ii) an amino acid sequence that is 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a light chain variable region sequence of SEQ ID NO: 10.
  • the anti-IL-13 antibody, or an IL- 13 -binding fragment thereof may comprise a heavy chain variable region sequence of SEQ ID NO: 8 and a light chain variable region sequence of SEQ ID NO: 10.
  • the anti-IL-13 antibody, or the IL- 13 -binding fragment thereof may comprise: (i) an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the heavy chain sequence of SEQ ID NO: 11; and/or (ii) an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the light chain sequence of SEQ ID NO: 12.
  • the anti-IL-13 antibody or an IL- 13 -binding fragment or IL- 13 -binding derivative thereof, comprises a heavy chain of SEQ ID NO: 11 and a light chain sequence of SEQ ID NO: 12.
  • One such antibody that can be used in the methods described herein is the anti-IL-13 antibody, tralokinumab (as described in the "International Nonproprietary Names for Pharmaceutical Substances (INN)" list 102 ( WHO Drug Information (2009) 23(4): pp 348)).
  • Tralokinumab is a fully human IgG4-lambda antibody, which specifically binds and neutralises human IL-13.
  • the invention provides an interleukin- 13 (IL-13) binding protein as described above (e.g. an anti-IL-13 antibody or IL-13 binding fragment thereof) for use in any method of treatment described herein, wherein the method comprises the steps of: (a) administering a first dose of the IL-13 binding protein to the subject; and (b) administering one or more secondary dose(s) of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject from 12 days to 35 days after the immediately preceding dose.
  • each secondary dose is administered to the subject from 12 days to 16 days after the immediately preceding dose, e.g. 14 days after the immediately preceding dose, or from 25 days to 31 days after the immediately preceding dose, e.g. about 4 weeks after the immediately preceding dose.
  • dose refers to the amount (mass) of IL-13 binding protein administered to the subject on the particular treatment day.
  • a dose of 300 mg of IL-13 binding protein means that on a treatment day a total of 300 mg of IL-13 binding protein is given to the subject.
  • a dose is administered in a single administration step (e.g. one injection).
  • one, two, three, four or more administration steps e.g. one, two, three, four or more injections
  • first dose is a single dose of IL-13 binding protein that is followed by one or more secondary dose(s).
  • the first dose may be preceded by one or more prior dose(s), or the “first dose” may be the initiation of treatment by the method described herein (in the latter case, this dose can therefore be referred to as the "baseline dose”).
  • baseline dose is referred to as the “baseline dose”.
  • secondary dose is one or more secondary dose(s); and the one or more secondary dose(s) may be followed by one or more tertiary dose(s).
  • immediate preceding dose means, in a sequence of multiple doses, the dose of IL-13 binding protein which is administered to a patient prior to the administration of the very next dose in the sequence, with no intervening doses of the IL-13 binding protein.
  • Dosing frequency is the frequency of administering a dose of the IL-13 binding protein. Thus, a decrease in dosing frequency means an increase in the time interval between doses. Common terminology used in relation to dosing frequency is QW (once weekly), Q2W (once every 2 weeks), Q3W (every 3 weeks), or Q4W (every 4 weeks).
  • the first dose may be from about 10 mg to about 600 mg of the IL-13 binding protein, from about 50 mg to 500 mg, from about 100 mg to about 400 mg, from about 250 mg to about 350 mg or from about 280 mg to about 320 mg of IL-13 binding protein.
  • the first dose is about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 400 mg, about 500 mg or about 600 mg.
  • the first dose is 600 mg or less, 500 mg or less, 400 mg or less, 300 mg or less, 200 mg or less, or 200 mg or less.
  • the first dose is about 600 mg of IL-13 binding protein (e.g. as illustrated in the examples).
  • Each secondary dose may be administered to the subject from 12 days to 35 days, from 12 days to 30 days, from 12 days to 25 days, from 12 days to 20 days, from 12 days to 16 days, from 12 days to 15 days, from 12 days to 14 days, from 18 days to 35 days, from 21 days to 35 days, from 22 days to 34 days, from 24 days to 32 days, from 25 days to 31 days, from 26 days to 30 days, or from 27 days to 29 days after the immediately preceding dose.
  • each secondary dose may be administered to the subject about 14 days (i.e. 2 weeks) after the immediately preceding dose (as exemplified herein).
  • the method may be carried out until it provides improvement in an AD-associated parameter and/or patient-related outcome as described herein.
  • the method may provide an improvement in an AD-associated parameter and/or patient-related outcome in around 2 weeks, around 3 weeks, around 12 weeks, around 3 months, around 16 weeks, around 24 weeks, around 26 weeks, around 6 months, around 32 weeks, around 36 weeks, around a year, around 52 weeks or more than 52 weeks.
  • the improvement in an AD-associated parameter and/or patient-related outcome is provided in around 16 weeks or 26 weeks.
  • the method may be continued until the subject reaches a low disease state.
  • the subject may reach a low disease state in around 4 weeks, around 8 weeks, around 12 weeks, around 3 months, around 16 weeks, around 24 weeks, around 26 weeks, around 6 months, around 32 weeks, around 36 weeks, around a year, around 52 weeks or more than 52 weeks.
  • the subject may reach a low disease state in around 16 weeks or 26 weeks.
  • the method may be carried out for at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 3 months, at least 16 weeks, at least 24 weeks, at least 26 weeks, at least 6 months, at least 32 weeks, at least 36 weeks, at least a year, or at least 52 weeks or more. In some cases, the method may be carried out for around 2 weeks, around 3 weeks, around 12 weeks, around 3 months, around 16 weeks, around 24 weeks, around 6 months, around 32 weeks, around 36 weeks, around a year, around 52 weeks. In preferred embodiments, the method is carried out for at least 26 weeks.
  • the phrase "low disease state” is an Investigator’s Global Assessment (IGA) score of 0 or 1 and/or > 75% improvement of Eczema Area and Severity Index (EASI-75) over baseline.
  • IGA Global Assessment
  • EASI-75 Eczema Area and Severity Index
  • Step (b) of the method i.e. administering one or more secondary dose(s) of the IL-13 binding protein to the subject
  • may be continued i.e. by administering more than one secondary dose
  • the one or more secondary dose(s) may be administered for at least 8 weeks, at least 12 weeks, at least 3 months, at least 16 weeks, at least 20 weeks, at least 24 weeks, at least 6 months, at least 28 weeks, at least 32 weeks, at least 36 weeks, at least a year, at least 52 weeks or more.
  • Step (b) of the method may be continued (i.e.
  • step (b) may be continued until the method provides improvement in an AD-associated parameter and/or patient-related outcome as described herein.
  • step (b) of may be continued to maintain improvement in an AD-associated parameter and/or patient-related outcome as described herein.
  • step (b) may be continued until the subject reaches a low disease state.
  • Each secondary dose may be from about 10 mg to about 600 mg of the IL-13 binding protein, from about 50 mg to 500 mg, from about 100 mg to about 400 mg, from about 250 mg to about 350 mg or from about 280 mg to about 320 mg of IL-13 binding protein.
  • each secondary dose is about 10 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 400 mg or about 500 mg.
  • each secondary dose is 600 mg or less, 500 mg or less, 400 mg or less, 300 mg or less, 200 mg or less or 200 mg or less.
  • each secondary dose is about 300 mg of IL-13 binding protein (e.g. as in the examples).
  • the first dose and one or more secondary dose(s) are the same amount (i.e. in milligrams) of IL-13 binding protein. In other embodiments, the first dose is greater than the one or more secondary doses. For example, in some embodiments the first dose is 600 mg and the one or more secondary doses is 300 mg.
  • the method comprises the steps of: (a) administering a first dose of about 600 mg of the IL 13 binding protein (e.g. tralokinumab) to the subject; and (b) administering one or more secondary dose(s) of about 300 mg of the IL-13 binding protein (e.g. tralokinumab) to the subject, wherein each secondary dose is administered to the subject about 2 weeks after the immediately preceding dose, optionally wherein the method is carried out for about 26 weeks.
  • each administration is by subcutaneous injection.
  • the first dose is a bolus dose which is double the amount of the doses following the bolus dose.
  • the first dose is a 600 mg dose and the dose(s) following the 600 mg dose is/are 300 mg dose(s).
  • the bolus dose is typically twice the amount of the dose administered with the next administration. For example, a dose of 600 mg is used as a bolus dose when the next dose administered is 300 mg.
  • the IL-13 binding protein (e.g. an anti-IL-13 antibody or an IL-13 -binding fragment thereof) may be administered by any appropriate method.
  • administration is parenteral, e.g. intradermal, intramuscular, intravenous and subcutaneous.
  • Subcutaneous administration is particularly preferred (e.g. as illustrated in the examples).
  • Each dose of the IL-13 binding protein may therefore be administered subcutaneously.
  • Administration is preferably in a "therapeutically effective amount", this being sufficient to show improvement or maintained improvement in one or more AD-associated parameter or patient-related outcome as described herein, or achievement of a low disease state.
  • Administration may be by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g. oral mucosa, rectal and intestinal mucosa, etc.).
  • epithelial or mucocutaneous linings e.g. oral mucosa, rectal and intestinal mucosa, etc.
  • Subcutaneous or intravenous delivery may be with a standard needle and syringe (e.g. including with a prefilled syringe). It is envisaged that the methods described herein will not be restricted to use in the clinic. Therefore, subcutaneous injection using a needle free device is also preferred.
  • Such delivery devices can be reusable or disposable. Numerous reusable pen and autoinjector delivery devices are known in the art and may find use in the present invention.
  • Examples include AUTOPENTM (Owen Mumford, Inc., Woodstock, UK), DISETRONICTM pen (Disetronic Medical Systems, Bergdorf, Switzerland), HUMALOG MIX 75/25TM pen, HUMALOGTM pen, HUMALIN 70/30TM pen (Eli Lilly and Co., Indianapolis, IN), NOVOPENTM 1, 11 and 111 (Nova Nordisk, Copenhagen, Denmark), NOVOPEN JUNIORTM (Nova Nordisk, Copenhagen, Denmark), BDTM pen (Becton Dickinson, Franklin Lakes, NJ), OPTIPENTM, OPTIPEN PROTM, OPTIPEN STARLETTM, and OPTICLIKTM (Sanofi-Aventis, Frankfurt, Germany).
  • Exemplary disposable pen delivery devices for subcutaneous delivery include the SOLOSTARTM pen (Sanofi-Aventis), the FLEXPENTM (Nova Nordisk), and the KWIKPENTM (Eli Lilly), the SURECLICKTM Autoinjector (Amgen, Thousand Oaks, CA), the PENLETTM (Haselmeier, Stuttgart, Germany), the EPIPEN (Dey, L.P.), and the HUMIRATM Pen (Abbott Labs, Abbott Park IL).
  • each dose of IL-13 binding protein is not necessarily administered in a single administration step (e.g. one injection or one tablet etc.). Indeed, depending on the concentration of the IL-13 binding protein (e.g. in the pharmaceutical composition), one, two, three, four or more administration steps (e.g. one, two, three, four or more injections) may be required to provide the subject with the required amount of IL-13 binding protein (e.g. a 300 mg dose, for example). Thus, in some embodiments, each dose of the IL-13 binding protein is administered in two or four injections (e.g. subcutaneously). In some embodiments, each injection provides 150 mg IL-13 binding protein and two injections are required for a 300 mg dose and four injections are required for a 600 mg dose. Typically subcutaneous injections have a volume of around 1.5 mL or less, such as a volume of from 0.2 to 1.5 mL, e.g. around 1 mL.
  • the methods described herein may be a monotherapy.
  • the term "monotherapy” is a therapy which uses a single drug to treat a disease or condition. Therefore, a subject that is treated with a monotherapy will receive only a single drug to treat the relevant disorder, i.e. AD.
  • an anti-IL-13 antibody monotherapy refers to a monotherapy which comprises the administration of anti-IL-13 antibody to the subject as the sole drug for the treatment of AD.
  • the methods described herein may be a combination therapy.
  • combination therapy is a therapy which uses more than one drug to treat a disease or condition.
  • a subject that is treated with a combination therapy will receive more than one drug (e.g. two, three or more) to treat AD.
  • the IL-13 binding protein is administered in combination with a topical therapy (such as a topical corticosteroid or a topical calcineurin inhibitor).
  • a topical therapy such as a topical corticosteroid or a topical calcineurin inhibitor.
  • the additional treatment e.g. TCS or TCI
  • TCS topical corticosteroid
  • TCI topical calcineurin inhibitor
  • the IL-13 binding protein is administered in combination with a second therapeutic agent selected from the group consisting of a topical corticosteroid, a topical calcineurin inhibitor, an anti-histamine, an emollient, or an anti-bacterial therapeutic.
  • a second therapeutic agent selected from the group consisting of a topical corticosteroid, a topical calcineurin inhibitor, an anti-histamine, an emollient, or an anti-bacterial therapeutic.
  • the IL-13 binding protein is administered in combination with a Group I, Group II, Group III or Group IV corticosteroid.
  • the IL-13 binding protein can be administered in combination with mometasone furoate (e.g. 0.1% cream).
  • the present invention envisages methods where each dose of the IL-13 binding protein (e.g. an anti-IL-13 antibody or an IL-13-binding fragment thereof) is administered as a pharmaceutical composition.
  • the pharmaceutical compositions may be formulated with suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like.
  • suitable carriers, excipients, and other agents that provide suitable transfer, delivery, tolerance, and the like.
  • a multitude of formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA.
  • the dose administered to a patient according to the methods described herein may be varied depending upon the age and the size of the patient, symptoms, conditions, route of administration, and the like.
  • the dose can be calculated according to body weight or body surface area.
  • the pharmaceutical compositions may comprise, in addition to the active ingredient (i.e. the IL-13 binding protein), a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
  • the precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. intravenous or subcutaneous.
  • Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form.
  • a tablet may comprise a solid carrier such as gelatin or an adjuvant.
  • Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.
  • the pharmaceutical composition may be a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability.
  • isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection.
  • Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.
  • the pharmaceutical composition may be a liquid formulation or a lyophilized formulation which is reconstituted before use.
  • excipients for a lyophilized formulation for example, sugar alcohols, or saccharides (e.g. mannitol or glucose) may be used.
  • the pharmaceutical composition is usually provided in the form of containers with defined volume, including sealed and sterilized plastic or glass vials, ampoules and syringes, as well as in the form of large volume containers like bottles.
  • the pharmaceutical composition is a liquid formulation.
  • the IL-13 binding protein may be present within the pharmaceutical composition at a concentration of from 1 mg/mL to 200 mg/mL, more preferably 150 mg/mL.
  • the pharmaceutical composition may be buffered to a pH of 5.2 to 5.7, most preferably 5.5 (e.g. ⁇ 0.1).
  • a pH of 5.2 to 5.7 most preferably 5.5 (e.g. ⁇ 0.1).
  • the selection of such a pH confers significant stability to the pharmaceutical composition.
  • alternative buffers that control the pH in this range include succinate, gluconate, histidine, citrate, phosphate, glutarate, cacodylate, sodium hydrogen maleate, tris(hydroxymethyl)aminomethane (Tris), 2-(N- morpholino)ethanesulphonic acid (MES), imidazole.
  • the buffer is acetate buffer, more preferably sodium acetate buffer.
  • the acetate buffer is present within the pharmaceutical composition in an amount of from 1 mM to 100 mM, more preferably from 30 mM to 70 mM, especially 50 mM.
  • references to "pharmaceutically acceptable excipient” includes references to any excipient conventionally used in pharmaceutical compositions.
  • excipients may typically include one or more surfactant, inorganic or organic salt, stabilizer, diluent, solubilizer, reducing agent, antioxidant, chelating agent, preservative and the like.
  • nonionic surfactants such as sorbitan fatty acid esters (e.g. sorbitan monocaprylate, sorbitan monolaurate, sorbitan monopalmitate), glycerine fatty acid esters (e.g. glycerine monocaprylate, glycerine monomyristate, glycerine monostearate), polyglycerine fatty acid esters (e.g. decaglyceryl monostearate, decaglyceryl distearate, decaglyceryl monolinoleate), polyoxyethylene sorbitan fatty acid esters (e.g.
  • nonionic surfactants such as sorbitan fatty acid esters (e.g. sorbitan monocaprylate, sorbitan monolaurate, sorbitan monopalmitate), glycerine fatty acid esters (e.g. glycerine monocaprylate, glycerine monomyristate, glycerine mono
  • polyoxyethylene lauryl ether polyoxyethylene polyoxypropylene alkyl ethers (e.g. polyoxyethylene polyoxypropylene glycol ether, polyoxyethylene polyoxypropylene propyl ether, polyoxyethylene polyoxypropylene cetyl ether), polyoxyethylene alkylphenyl ethers (e.g. polyoxyethylene nonylphenyl ether), polyoxyethylene hydrogenated castor oils (e.g. polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil), polyoxyethylene beeswax derivatives (e.g. polyoxyethylene sorbitol beeswax), polyoxyethylene lanolin derivatives (e.g.
  • polyoxyethylene lanolin polyoxyethylene lanolin
  • polyoxyethylene fatty acid amides e.g. polyoxyethylene stearyl amide
  • anionic surfactants such as C10-C18 alkyl sulfates salts (e.g. sodium cetyl sulfate, sodium lauryl sulfate, sodium oleyl sulfate), polyoxyethylene C10-C18 alkyl ether sulfates salts with an average of 2 to 4 moles of ethylene oxide (e.g. sodium polyoxyethylene lauryl sulfate), and C8-C18 alkyl sulfosuccinate ester salts (e.g.
  • sodium lauryl sulfosuccinate ester sodium lauryl sulfosuccinate ester
  • natural surfactants such as lecithin, glycerophospholipid, sphingophospholipids (e.g. sphingomyelin), and sucrose esters of C12-C18 fatty acids.
  • the surfactant may be selected from polyoxyethylene sorbitan fatty acid esters. Preferred surfactants are polysorbate 20, 21, 40, 60, 65, 80, 81 and 85, most preferably polysorbate 20 and 80, especially polysorbate 80.
  • the surfactant is present within the pharmaceutical composition in an amount of from 0.001% to 0.1% (w/w), more preferably 0.005% and 0.05% (w/w), especially 0.01% (w/w).
  • Examples of a typical inorganic salt include: sodium chloride, potassium chloride, calcium chloride, sodium phosphate, sodium sulphate, ammonium sulphate, potassium phosphate and sodium bicarbonate or any other sodium, potassium or calcium salt.
  • the inorganic salt is sodium chloride.
  • the inorganic salt is present within the pharmaceutical composition in an amount of from 10 mM to 200 mM, more preferably from 60 mM to 130 mM, especially 85 mM.
  • a reducing agent include N-acetylcysteine, Nacetylhomocysteine, thioctic acid, thiodiglycol, thioethanolamine,thioglycerol, thiosorbitol, thioglycolic acid and a salt thereof, sodium thiosulfate, glutathione, and a C1-C7 thioalkanoic acid.
  • antioxidants examples include erythorbic acid, dibutylhydroxytoluene, butylhydroxyanisole, alpha-tocopherol, tocopherol acetate, L-ascorbic acid and a salt thereof, L-ascorbic acid palmitate, L-ascorbic acid stearate, sodium bisulfite, sodium sulfite, triamyl gallate and propyl gallate.
  • Examples of a chelating agent include disodium ethylenediaminetetraacetate (EDTA), sodium pyrophosphate and sodium metaphosphate.
  • Examples of a stabiliser include creatinine, an amino acid selected from histidine, alanine, glutamic acid, glycine, leucine, phenylalanine, methionine, isoleucine, proline, aspartic acid, arginine, lysine and threonine, a carbohydrate selected from sucrose, trehalose, sorbitol, xylitol and mannose, surfactants selected from polyethylene glycol (PEG; e.g. PEG3350 or PEG 4000) or polyoxyethylene sorbitan fatty acid esters (e.g. polysorbate 20 or polysorbate 80), or any combination thereof.
  • PEG polyethylene glycol
  • PEG polyoxyethylene sorbitan fatty acid esters
  • the stabiliser comprises a single carbohydrate (e.g. trehalose).
  • the stabilizer comprises an amino acid in combination with a carbohydrate (e.g. trehalose and alanine or trehalose, alanine and glycine).
  • the stabiliser comprises an amino acid in combination with a carbohydrate and a surfactant (e.g. trehalose, alanine and PEG3350; trehalose, proline and PEG3350; trehalose, alanine and polysorbate 80; trehalose, proline and polysorbate 80; trehalose, alanine, glycine and PEG3350; trehalose, alanine, glycine and polysorbate 80).
  • a surfactant e.g. trehalose, alanine and PEG3350; trehalose, proline and PEG3350; trehalose, proline and polysorbate 80; trehalose, alanine, glycine and PEG3350; trehalose, alanine, g
  • the stabiliser comprises an amino acid in combination with a surfactant (e.g. alanine and PEG3350 or alanine, glycine and PEG3350).
  • a surfactant e.g. alanine and PEG3350 or alanine, glycine and PEG3350.
  • the stabiliser comprises a carbohydrate in combination with a surfactant (e.g. trehalose and PEG3350 or trehalose and polysorbate 80).
  • a preservative examples include octadecyldimethylbenzyl ammonium chloride, hexamethonium chloride, benzalkonium chloride (a mixture of alkylbenzyldimethylammonium chlorides in which the alkyl groups are long chain compounds), benzethonium chloride, aromatic alcohols such as phenol, butyl and benzyl alcohol, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, 3-pentanol, and m-cresol.
  • the pharmaceutical composition comprises an IL-13 binding protein as described herein, a surfactant and an inorganic salt buffered to a pH of 5.5 ⁇ 0 .1 with acetate buffer.
  • the pharmaceutical composition comprises an IL-13 binding protein as described herein, sodium chloride and polysorbate 80, buffered to a pH of 5.5 ⁇ 0 .1 with sodium acetate buffer.
  • the pharmaceutical composition comprises an IL-13 binding protein as described herein (e.g. tralokinumab), 50 mM sodium acetate buffer, 85 mM sodium chloride, 0.01% (w/v) polysorbate 80, wherein the pharmaceutical composition has a pH of 5.5.
  • an IL-13 binding protein as described herein (e.g. tralokinumab), 50 mM sodium acetate buffer, 85 mM sodium chloride, 0.01% (w/v) polysorbate 80, wherein the pharmaceutical composition has a pH of 5.5.
  • the pharmaceutical composition comprises 150 mg/mL of an IL-13 antibody (e.g. tralokinumab), 50 mM sodium acetate buffer, 85 mM sodium chloride, 0.01% (w/v) polysorbate 80, wherein the pharmaceutical composition has a pH of 5.5.
  • an IL-13 antibody e.g. tralokinumab
  • 50 mM sodium acetate buffer 85 mM sodium chloride
  • 0.01% (w/v) polysorbate 80 0.01%
  • methods "comprising" a number of steps do not require the steps to be performed in a particular order.
  • a method comprises a number of sequentially numbered or alphabetical steps (e.g. (1), (2), (3); (i), (ii), (iii); or (a), (b), (c) etc.)
  • treat means to alleviate (reduce, minimise, or eliminate) symptoms, or to reduce, minimise or eliminate the causation of symptoms either on a temporary or permanent basis.
  • All publications mentioned herein are incorporated by reference in their entirety.
  • Example 1 Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial
  • ECZTRA 7 was a randomized, double-blinded, multicenter, placebo-controlled Phase 3 trial.
  • Eligible patients were randomized 1:1 to subcutaneous tralokinumab 300 mg every 2 weeks with TCS as needed or placebo with TCS as needed for a treatment period of 26 weeks, following a 600 mg loading dose on Day 0.
  • dupilumab-experienced patients are defined as those with a confirmed history of dupilumab use prior to the trial, and dupilumab-reffactory patients as those who discontinued dupilumab due to lack of efficacy or adverse events per queries prior to unblinding.
  • Cochran-Mantel-Haenszel with treatment as only strata was used for analysis.
  • the median (interquartile range, IQR) EASI and percent of patients with an IGA of 4 were 35.5 (24.8, 39.6) and 57.1% among dupilumab-experienced patients and 28.7 (22.4, 39.5) and 49.0% among dupilumab-nai ' ve patients, respectively.
  • AD atopic dermatitis
  • EASI-50 at least 50% reduction in Eczema Area and Severity Index score EASI-75, at least 75% reduction in Eczema Area and Severity Index score EQ-5D-5L, EuroQoL 5-Dimension Health Questionnaire 5 Level HADS, Hospital Anxiety and Depression Scale HRQoL, Health-related quality of life IGA, Investigator’s Global Assessment
  • TCS topical corticosteroids
  • An interleukin- 13 (IL-13) binding protein for use in a method of treating atopic dermatitis (AD) in a subject, wherein the AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signalling, such as an anti-IL4Ra antibody (e.g. dupilumab) and wherein the method comprises administering the IL-13 binding protein to the subject.
  • AD atopic dermatitis
  • an anti-IL4Ra antibody e.g. dupilumab
  • AD atopic dermatitis
  • an agent that inhibits IL-13 and IL-4 signalling such as an anti-IL4Ra antibody (e.g. dupilumab)
  • the method comprises the step of administering the IL-13 binding protein to the subject.
  • IL-13 binding protein for use according to clause 1 or the method according to clause 2, wherein the method comprises the step of selecting a subject in which AD is inadequately controlled by an agent that inhibits IL-13 and IL-4 signalling, such as an anti-IL4Ra antibody (e.g. dupilumab).
  • an agent that inhibits IL-13 and IL-4 signalling such as an anti-IL4Ra antibody (e.g. dupilumab).
  • An IL-13 binding protein for use in a method of treating atopic dermatitis in a subject who has experienced conjunctivitis when treated with an antibody that inhibits IL-4 and IL-13 signalling, such as an anti-IL4Ra antibody (e.g. dupilumab), wherein the method comprises administering the IL-13 binding protein to the subject.
  • an antibody that inhibits IL-4 and IL-13 signalling such as an anti-IL4Ra antibody (e.g. dupilumab)
  • an anti-IL4Ra antibody e.g. dupilumab
  • an antibody that inhibits IL-4 and IL-13 signalling such as an anti-IL4Ra antibody (e.g. dupilumab)
  • the method comprises administering the IL-13 binding protein to the subject.
  • IL-13 binding protein for use according to clause 4 or the method according to clause 5, wherein the method comprises the step of selecting a subject who has experienced conjunctivitis when treated with an antibody that inhibits IL-4 and IL- 13 signalling, such as an anti-IL4Ra antibody (e.g. dupilumab).
  • an antibody that inhibits IL-4 and IL- 13 signalling such as an anti-IL4Ra antibody (e.g. dupilumab).
  • IL- 13 binding protein for use or the method according to any one of the preceding clauses, wherein the agent that inhibits IL-13 and IL-14 signalling (e.g. dupilumab) does not result in >75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline.
  • the agent that inhibits IL-13 and IL-14 signalling e.g. dupilumab
  • EASI-75 Eczema Area and Severity Index
  • IL- 13 binding protein for use or the method according to any one of the preceding clauses, wherein the method comprises the steps of: (a) administering a first dose of the IL-13 binding protein to the subject; and (b) administering one or more secondary dose(s) of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject from 12 days to 35 days after the immediately preceding dose.
  • each secondary dose is administered to the subject about 2 weeks or about 4 weeks after the immediately preceding dose.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the method is carried out for at least 2 weeks, at least 3 weeks, at least 12 weeks, at least 3 months, at least 16 weeks, at least 24 weeks, at least 26 weeks, at least 6 months, at least 32 weeks, at least 36 weeks, at least a year, or at least 52 weeks or more.
  • IL-13 binding protein for use or the method according to clause 13, wherein the method comprises the steps of: (a) administering a first dose of about 600 mg of the IL 13 binding protein to the subject; and (b) administering one or more secondary dose(s) of about 300 mg of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject from 12 days to 35 days after the immediately preceding dose.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the AD is moderate-to-severe or severe AD.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the IL-13 binding protein is administered subcutaneously.
  • the IL-13 binding protein for use or the method according to any one of the preceding clauses wherein the IL-13 binding protein is administered as a pharmaceutical composition comprising 50 mM sodium acetate buffer, 85 mM sodium chloride, 0.01% (w/v) polysorbate 80, wherein the pharmaceutical composition has a pH of 5.5.
  • the IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the IL-13 binding protein is an anti-IL-13 antibody, or an IL-13 -binding fragment thereof.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the IL-13 binding protein is a monoclonal anti-IL-13 antibody, or an IL-13 -binding fragment thereof.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the IL-13 binding protein is a human anti-IL-13 antibody, or an IL-13 -binding fragment thereof.
  • IL-13 binding protein for use or the method according to any one of clauses 19-21, wherein the IL-13 antibody is an IgG4 antibody.
  • IL-13 binding protein for use or the method according to any one of clauses 19-22, wherein the IL-13-binding fragment is selected from a Fab, Fab', F(ab')2, Fd, Fv, single-chain Fv (scFv), or disulfide-linked Fvs (sdFv).
  • the IL-13 binding protein for use or the method according to any one of clauses 19-23, wherein the anti-IL-13 antibody, or the IL-13 -binding fragment thereof, comprises: a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence of SEQ ID NO: 1 ; a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence of SEQ ID NO:2; a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence of SEQ ID NO:3; a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence of SEQ ID NO:4; a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence of SEQ ID NO:5; and a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence of SEQ ID NO:6.
  • HCDR1 heavy chain complementarity determining region 1
  • HCDR2 comprising an amino acid sequence of SEQ ID NO:
  • the IL-13 binding protein for use or the method according to any one of clauses 19- 24, wherein the anti-IL-13 antibody, or the IL-13 -binding fragment thereof, comprises a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein:
  • HCVR heavy chain variable region
  • LCVR light chain variable region
  • the heavy chain variable region comprises: a heavy chain complementarity determining region 1 (HCDR1) comprising an amino acid sequence of SEQ ID NO: 1 ; a heavy chain complementarity determining region 2 (HCDR2) comprising an amino acid sequence of SEQ ID NO:2; and a heavy chain complementarity determining region 3 (HCDR3) comprising an amino acid sequence of SEQ ID NO:3; and
  • HCDR1 heavy chain complementarity determining region 1
  • HCDR2 heavy chain complementarity determining region 2
  • HCDR3 heavy chain complementarity determining region 3
  • the light chain variable region comprises: a light chain complementarity determining region 1 (LCDR1) comprising an amino acid sequence of SEQ ID NO:4; a light chain complementarity determining region 2 (LCDR2) comprising an amino acid sequence of SEQ ID NO:5; and a light chain complementarity determining region 3 (LCDR3) comprising an amino acid sequence of SEQ ID NO:6.
  • LCDR1 light chain complementarity determining region 1
  • LCDR2 light chain complementarity determining region 2
  • LCDR3 comprising an amino acid sequence of SEQ ID NO:6.
  • the IL-13 binding protein for use or the method according to any one of clauses 19-26, wherein the anti-IL-13 antibody, or the IL-13 -binding fragment thereof, comprises a heavy chain variable region sequence of SEQ ID NO: 8 and a light chain variable region sequence of SEQ ID NO: 10.
  • IL-13 binding protein for use or the method according to clause 29, wherein the anti-IL-13 antibody is tralokinumab.
  • IL- 13 binding protein for use or the method according to any one of the preceding clauses, wherein the IL-13 binding protein is administered as a monotherapy.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the IL-13 binding protein is administered in combination with a second therapeutic agent selected from the group consisting of a topical corticosteroid, a topical calcineurin inhibitor, an anti-histamine, an emollient, or an anti-bacterial therapeutic.
  • a second therapeutic agent selected from the group consisting of a topical corticosteroid, a topical calcineurin inhibitor, an anti-histamine, an emollient, or an anti-bacterial therapeutic.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses wherein the agent that inhibits IL-13 and IL-4 signalling is an antibody or antigen binding fragment thereof.
  • IL-13 binding protein for use or the method according to clause 34, wherein the agent that inhibits IL-13 and IL-4 signalling is an antigen binding fragment, wherein the antigen binding fragment is selected from a Fab, Fab', F(ab')2, Fd, Fv, singlechain Fv (scFv), or disulfide-linked Fvs (sdFv).
  • IL-13 binding protein for use or the method according to any one of clauses 34 or 35, wherein the agent that inhibits IL-13 and IL-4 signalling is an antibody or antigen binding fragment thereof that binds to IL-4Ra.
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the method achieves >50% improvement of Eczema Area and Severity Index (EASI-50) compared to baseline.
  • EASI-50 Eczema Area and Severity Index
  • IL-13 binding protein for use or the method according to any one of the preceding clauses, wherein the method achieves >75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline.
  • EASI-75 Eczema Area and Severity Index
  • the IL-13 binding for use or the method according to any one of the preceding clauses, wherein the method comprises (a) administering a first dose of about 600 mg of the IL-13 binding protein to the subject; and (b) administering one or more secondary dose(s) of about 300 mg of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject 2 weeks or 4 weeks after the immediately preceding dose, wherein the IL-13 binding protein is an antibody comprising a heavy chain variable region sequence shown as SEQ ID NO: 8 and a light chain variable region sequence shown as SEQ ID NO: 10, wherein the method is carried out for at least 26 weeks and wherein the method achieves >75% improvement of Eczema Area and Severity Index (EASI-75) compared to baseline at week 26.
  • EASI-75 Eczema Area and Severity Index

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement de la dermatite atopique chez un sujet à l'aide d'une protéine de liaison de l'interleukine-13 (IL-13), tel qu'un anticorps anti-IL-13 ou un fragment de liaison à l'IL-13 associé.
PCT/EP2022/065851 2021-06-11 2022-06-10 Méthodes de traitement de la dermatite atopique et d'affections correspondantes Ceased WO2022258814A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2023575802A JP2024522620A (ja) 2021-06-11 2022-06-10 アトピー性皮膚炎及び関連する障害の治療方法
CA3221119A CA3221119A1 (fr) 2021-06-11 2022-06-10 Methodes de traitement de la dermatite atopique et d'affections correspondantes
IL309053A IL309053A (en) 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders
AU2022289697A AU2022289697A1 (en) 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders
US18/566,712 US20250059269A1 (en) 2021-06-11 2022-06-10 Methods for treating atopic dermatitis and related disorders
EP22733594.0A EP4351641A1 (fr) 2021-06-11 2022-06-10 Méthodes de traitement de la dermatite atopique et d'affections correspondantes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2108379.5 2021-06-11
GBGB2108379.5A GB202108379D0 (en) 2021-06-11 2021-06-11 Methods for treating a topic dermatitis and related disorders

Publications (1)

Publication Number Publication Date
WO2022258814A1 true WO2022258814A1 (fr) 2022-12-15

Family

ID=76954592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/065851 Ceased WO2022258814A1 (fr) 2021-06-11 2022-06-10 Méthodes de traitement de la dermatite atopique et d'affections correspondantes

Country Status (9)

Country Link
US (1) US20250059269A1 (fr)
EP (1) EP4351641A1 (fr)
JP (1) JP2024522620A (fr)
AU (1) AU2022289697A1 (fr)
CA (1) CA3221119A1 (fr)
GB (1) GB202108379D0 (fr)
IL (1) IL309053A (fr)
TW (1) TW202317184A (fr)
WO (1) WO2022258814A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024170485A1 (fr) * 2023-02-13 2024-08-22 Intervet International B.V. Anticorps canins dirigés contre l'il-13 canine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007699A2 (fr) 2003-07-15 2005-01-27 Cambridge Antibody Technology Limited Molecules d'anticorps humains anti-il13
WO2007036745A2 (fr) 2005-09-30 2007-04-05 Medimmune Limited Composition comprenant un anticorps anti-interleukine 13
WO2018158332A1 (fr) 2017-03-01 2018-09-07 Medimmune Limited Formulations d'anticorps monoclonaux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007699A2 (fr) 2003-07-15 2005-01-27 Cambridge Antibody Technology Limited Molecules d'anticorps humains anti-il13
WO2007036745A2 (fr) 2005-09-30 2007-04-05 Medimmune Limited Composition comprenant un anticorps anti-interleukine 13
WO2018158332A1 (fr) 2017-03-01 2018-09-07 Medimmune Limited Formulations d'anticorps monoclonaux

Non-Patent Citations (32)

* Cited by examiner, † Cited by third party
Title
"European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European task force on atopic dermatitis", DERMATOLOGY, vol. 186, no. 1, 1993, pages 23 - 31
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
AGNIHOTRI G ET AL.: "A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis", DRUGS IN R&D, vol. 19, 2019, pages 311 - 318
ANONYMOUS: "Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 - Full Text View - ClinicalTrials.gov", 26 October 2021 (2021-10-26), XP055962085, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT03761537> [retrieved on 20220919] *
BACHERT C ET AL.: "Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial", JAMA, vol. 315, 2016, pages 469 - 479
CASTRO M ET AL.: "Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma", N ENGL J MED, vol. 378, 2018, pages 2486 - 2496, XP009510100, DOI: 10.1056/NEJMoa1804092
CHARMAN ET AL.: "The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients perspective", ARCH DERMATOL., vol. 140, no. 12, 2004, pages 1513 - 1519
EICHENFIELD ET AL., J. AM. ACAD. DERMATOL., vol. 70, 2014, pages 338 - 351
FINLAY ET AL.: "Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use", CLIN EXP DERMATOL., vol. 19, no. 3, 1994, pages 210 - 216
GONÇALVES FRANCISCA ET AL: "Selective IL-13 inhibitors for the treatment of atopic dermatitis", DRUGS IN CONTEXT, vol. 10, 30 March 2021 (2021-03-30), pages 1 - 17, XP055962946, Retrieved from the Internet <URL:https://www.drugsincontext.com/wp-content/uploads/2021/04/dic.2021-1-7.pdf> DOI: 10.7573/dic.2021-1-7 *
GREINER W ET AL.: "A single European currency for EQ-5D health states. Results from a six-country study", THE EUROPEAN JOURNAL OF HEALTH ECONOMICS: HEPAC : HEALTH ECONOMICS IN PREVENTION AND CARE, vol. 4, no. 3, 2003, pages 222 - 31
GUTERMUTH J ET AL: "509 Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post-hoc subgroup analysis of the ECZTRA 7 trial", BRITISH JOURNAL OF DERMATOLOGY, vol. 185, no. 3, 2 September 2021 (2021-09-02), Hoboken, USA, XP055962416, ISSN: 0007-0963, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjd.20648> DOI: 10.1111/bjd.20648 *
HANIFIN ET AL., THE ECZEMA AREA AND SEVERITY INDEX (EASI): ASSESSMENT OF RELIABILITY IN ATOPIC DERMATITIS. EASI EVALUATOR GROUP. EXPERIMENTAL DERMATOLOGY, vol. 10, no. 1, 2001, pages 11 - 18
HIRANO I ET AL.: "Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis", GASTROENTEROLOGY, vol. 158, 2020, pages 111 - 122
LEUNG, D.Y.GUTTMAN-YASSKY, E.: "Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches", J ALLERGY CLIN IMMUNOL., vol. 134, 2014, pages 769 - 779
LINDER C. ET AL: "Analysis of non-responders to dupilumab in clinical practice: a cohort study", JEADV. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY., vol. 35, no. 3, 1 March 2021 (2021-03-01), NL, XP055966368, ISSN: 0926-9959, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jdv.16900> DOI: 10.1111/jdv.16900 *
MAY, R.D.MONK, P.D.COHEN, E.S.MANUEL, D.DEMPSEY, F.DAVIS, N.H. ET AL.: "Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma", BR J PHARMACOL., vol. 166, 2012, pages 177 - 193, XP071171088, DOI: 10.1111/j.1476-5381.2011.01659.x
NOMURA, I.GOLEVA, E.HOWELL, M.D.HAMID, Q.A.ONG, P.Y.HALL, C.F. ET AL.: "Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes", J IMMUNOL., vol. 171, 2003, pages 3262 - 3269
POPOVIC ET AL., J. MOL. BIOL., vol. 429, no. 2, 2017, pages 208 - 219
SILVERBERG J.I. ET AL: "Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial*", BRITISH JOURNAL OF DERMATOLOGY, vol. 184, no. 3, 22 February 2021 (2021-02-22), Hoboken, USA, pages 450 - 463, XP055919670, ISSN: 0007-0963, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjd.19573> DOI: 10.1111/bjd.19573 *
SILVERBERG JONATHAN I ET AL: "Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis A phase 2b randomized study", ANNALS OF ALLERGY, ASTHMA, ELSEVIER, AMSTERDAM, NL, vol. 126, no. 5, 15 December 2020 (2020-12-15), pages 576, XP086559305, ISSN: 1081-1206, [retrieved on 20201215], DOI: 10.1016/J.ANAI.2020.12.004 *
SIMPSON EL ET AL.: "Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis", N ENGL J MED, vol. 376, 2017, pages 1090 - 1091
SIMPSON ERIC ET AL: "Safety of specifically targeting interleukin-13 with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled Phase 3 and Phase 2 trials", 13 December 2020 (2020-12-13), XP055962224, Retrieved from the Internet <URL:https://revolutionizingad.com/images/resources/Dec2020VirtualConf/Posters/344_2131_-_RAD_Simpson_-_Safety_E12352b.pdf> *
TAZAWA, T.SUGIURA, H.SUGIURA, Y.UEHARA, M.: "Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis", ARCH DERMATOL RES., vol. 295, 2004, pages 459 - 464
THYSSEN JP ET AL.: "Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis", J AM ACAD DERMATOL, vol. 77, 2017, pages 280 - 286
WARE JEJSHERBOURNE CD: "The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection", MED CARE, vol. 30, no. 6, 1992, pages 473 - 83
WOLLENBERG A ET AL.: "Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment", J ALLERGY CLIN IMMUNOL PRACT, 2018
WOLLENBERG A. ET AL: "Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*", BRITISH JOURNAL OF DERMATOLOGY, vol. 184, no. 3, 30 December 2020 (2020-12-30), Hoboken, USA, pages 437 - 449, XP055919673, ISSN: 0007-0963, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1111/bjd.19574> DOI: 10.1111/bjd.19574 *
WOLLENBERG ANDREAS ET AL: "Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 143, no. 1, 12 June 2018 (2018-06-12), pages 135 - 141, XP085572598, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2018.05.029 *
WOLLENBERG, AORANJE, A.DELEURAN, M.SIMON, D.SZALAI, Z.KUNZ, B. ET AL.: "ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients", J EUR ACAD DERMATOL VENEREOL., vol. 30, 2016, pages 729 - 747
WOLLENBERG, J. ALLERGY CLIN. IMMUNOL., vol. 143, no. 1, 2019, pages 135 - 141
ZIGMOND ASSNAITH RP: "The hospital anxiety and depression scale", ACTA PSYCHIATR SCAND, vol. 67, no. 6, 1983, pages 361 - 70

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024170485A1 (fr) * 2023-02-13 2024-08-22 Intervet International B.V. Anticorps canins dirigés contre l'il-13 canine

Also Published As

Publication number Publication date
JP2024522620A (ja) 2024-06-21
GB202108379D0 (en) 2021-07-28
IL309053A (en) 2024-02-01
US20250059269A1 (en) 2025-02-20
AU2022289697A1 (en) 2023-12-21
CA3221119A1 (fr) 2022-12-15
TW202317184A (zh) 2023-05-01
EP4351641A1 (fr) 2024-04-17

Similar Documents

Publication Publication Date Title
US11167004B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
AU2017332732B2 (en) Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
AU2020326713A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
KR20210010518A (ko) Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
EP4126951A1 (fr) Méthodes de traitement de la dermatite atopique par administration d&#39;un antagoniste de l&#39;il-4r
US12187788B2 (en) Methods for treating atopic dermatitis and related disorders
US20230167171A1 (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
US20250059269A1 (en) Methods for treating atopic dermatitis and related disorders
US20230287099A1 (en) Methods for treating atopic dermatitis and related disorders
US20240400669A1 (en) Methods for treating atopic dermatitis and related disorders
RU2801204C2 (ru) Способ лечения атопического дерматита посредством введения ингибитора ил-4r
HK40010552A (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
HK40010552B (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22733594

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 3221119

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 309053

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2022289697

Country of ref document: AU

Ref document number: AU2022289697

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P6003180/2023

Country of ref document: AE

ENP Entry into the national phase

Ref document number: 2023575802

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023025533

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2022289697

Country of ref document: AU

Date of ref document: 20220610

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022733594

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022733594

Country of ref document: EP

Effective date: 20240111

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112023025533

Country of ref document: BR

Free format text: COM BASE NA PORTARIA/INPI/NO 48/2022, APRESENTE NOVO CONTEUDO DE LISTAGEM POIS O CONTEUDODA LISTAGEM APRESENTADA NA PETICAO NO 870240000915 DE 04/01/2024 POSSUI O CAMPO 110 DIVER-GENTE DO PEDIDO EM QUESTAO. A EXIGENCIA DEVE SER RESPONDIDA EM ATE 60 (SESSENTA) DIAS DE SUAPUBLICACAO E DEVE SER REALIZADA POR MEIO DA PETICAO GRU CODIGO DE SERVICO 207.

ENP Entry into the national phase

Ref document number: 112023025533

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20231205